1. Academic Validation
  2. Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons

Discovery of 5-phenyl-3-ureidothiophene-2-carboxamides as protective agents for ALS patient iPSC-derived motor neurons

  • Bioorg Med Chem Lett. 2024 Sep 3:113:129935. doi: 10.1016/j.bmcl.2024.129935.
Haruhiko Hattori 1 Kazuya Osumi 2 Masamichi Tanaka 2 Tadamasa Arai 2 Kazumi Nishimura 2 Naoyoshi Yamamoto 2 Keiko Sakamoto 2 Yasufumi Goto 2 Yuji Sugawara 2
Affiliations

Affiliations

  • 1 Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan. Electronic address: haruhiko.hattori.e3@mail.toray.
  • 2 Pharmaceutical Research Laboratories, Toray Industries, Inc., 6-10-1 Tebiro, Kamakura, Kanagawa 248-8555, Japan.
Abstract

We discovered novel neuroprotective compounds by phenotypic screening using SOD1-mutant amyotrophic lateral sclerosis (ALS) patient induced pluripotent stem cell (iPSC)-derived motor neurons. Mechanistic analysis showed that the protective effect of initial hit compound 1 was likely due to the inhibition of MAP4Ks, including MAP4K4, a member of the MAP4K kinase family. Structural transformation led to compound 15f, which showed improved MAP4K4 inhibitory activity and superior neuroprotective effects compared to 1 in motor neurons. The results suggest that structural optimization based on MAP4K4 inhibitory activity might improve the neuroprotective effect of this series of compounds.

Keywords

Neuroprotective; Patient iPSCs; Phenotypic screening.

Figures
Products